All three tenses have at least two readings, so the archetype blend applies as printed.
All nine metrics read as filed from the record.
What did they actually do?
Has it survived what it has been through?
2 warning events since 2017; the latest 2018-03-01.
From the record
Puma Biotechnology Inc's filings since 2017 show 2 warning events of 2 kinds: an auditor change (8-K item 4.01, the latest 2017-03-24); a late-report notice (Form NT 10-K or NT 10-Q, the latest 2018-03-01) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+30.2% a year over 9 filed years; profitable in 4 of 9.
From the record
Puma Biotechnology Inc's 9 filed years say what it did: revenue went from $28 million in fiscal 2017 to $228 million in fiscal 2025, up 30.2% a year; it rose in 4 of 8 years; the deepest fall was 17% from fiscal 2019 to fiscal 2020; net income was positive in 4 of 9 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
Share count grew 4.1% a year. 0% of cash flow returned. Insiders: 17 sales, 0 purchases.
From the record
Over the 3 fiscal years to 2025-12-31, Puma Biotechnology Inc's diluted share count grew about 4.1% a year, and dividends and buybacks returned about 0% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 17 sales (16 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-09-30 (their Form 4 filings).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they doing right now?
Is it financially healthy right now?
ROE 24%: 24¢ of profit per shareholder dollar. Leverage 40%: owes 40¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Puma Biotechnology Inc earned about 24 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 79 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 40 cents per dollar of assets, and net share issuance: its share count grew 3.2% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 34% of 315 in its family; net margin 13.6%.
From the record
Puma Biotechnology Inc's standing among 315 graded names in its industry family: revenue of $228 million in fiscal 2025 ranks in the top 27% by size; a net margin of 13.6% ranks in the top 15%; revenue growth of 0% a year over the last 3 filed years ranks in the bottom 38% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
top 12% of 315 in its family for leadership; chief executive since 2011.
From the record
Puma Biotechnology Inc's leadership, from its insiders' filings and its current reports: the chief executive on the record is Auerbach, Alan H (President and CEO, as filed), filing under that title since 2011-10-11, 15.1 years (top 5% of its family); the 10 officers and directors filing in the last fifteen months have been on the record a median of 8.8 years (top 14%); 2 officer or director changes were reported on Form 8-K since 2023-11-13, against the 10 people in charge now (top 16%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
bottom 48% of 273 in its family for room to expand.
From the record
Puma Biotechnology Inc's room to grow, from the newest filed statements (fiscal 2025): cash of $30 million against debt of $23 million leaves 3.2% of its assets as net cash, bottom 17% of its family; cash from operations less capital spending is 18.3% of revenue (top 15%); a gross margin of 74.5% (top 42%); research spending of 27.2% of revenue (bottom 33%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 37% of 306 in its family for growth drivers.
From the record
Puma Biotechnology Inc's growth drivers, from the filed years to fiscal 2025: revenue grew 0% a year over the last three filed years against 30.2% over all 9, slowing (bottom 20% of its family); the newest year grew -0.9% (bottom 36%); research spending grew 5.9% a year (top 45%) (its annual reports). Puma Biotechnology Inc reported 2 product lines in fiscal 2025: Product at $204 million (89%), Royalty at $24 million (11%); 1 of 2 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 42% of 233 in its family for expectations against reality.
From the record
Puma Biotechnology Inc's newest year against its own record: revenue of $228 million in fiscal 2025 came in 1.4% below the $232 million its prior three years' pace pointed to (top 48% of its family); net income of $31 million against a prior three-year average of $17 million (top 22%); a net margin of 13.6% against 7.4% before (bottom 45%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made